文献速递肾小球疾病

PROTECT试验:IgA肾病中完全蛋白尿缓解与肾功能保护的关联

Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-12-22

该研究为PROTECT三期试验的事后分析,纳入404例接受sparsentan或厄贝沙坦治疗的IgA肾病患者。结果显示,达到完全蛋白尿缓解(<0.3 g/d)的患者eGFR下降更慢、肾脏复合终点事件更少,支持将蛋白尿控制在0.3 g/d以下的指南推荐。

要点

  • 完全蛋白尿缓解(<0.3 g/d)与更好的eGFR保留和更少的肾衰竭事件相关。
  • CR110患者eGFR年下降速率显著慢于非CR患者(-0.7 vs -4.2 ml/min/1.73m²/年)。
  • CR110患者肾脏复合终点事件发生率1%,非CR患者为14%。

核心结论

  • 在PROTECT试验中,达到完全蛋白尿缓解(CR36或CR110)的患者eGFR保留更好、肾衰竭事件更少,安全性相似。
  • 数据支持将IgA肾病患者蛋白尿理想控制在<0.3 g/d的指南推荐。

研究设计与样本

  • PROTECT三期随机双盲试验的事后分析,纳入404例随机并接受研究药物的成人IgA肾病患者。
  • 比较达到CR(尿蛋白排泄<0.3 g/d)者与未达到者的肾功能,无论原始治疗分组。

主要发现

  • 404例中43例(11%)达到CR36,85例(21%)达到CR110。
  • CR110患者eGFR绝对变化为-4.0 ml/min/1.73m²,非CR患者为-8.6 ml/min/1.73m²。
  • CR110患者eGFR年下降速率为-0.7 ml/min/1.73m²/年,非CR患者为-4.2 ml/min/1.73m²/年。
  • CR110患者肾脏复合终点事件发生率为1%,非CR患者为14%。
  • CR110患者更易发生低血压相关治疗中出现的不良事件,更少发生高血压相关不良事件。

关键数值与推荐

  • 完全蛋白尿缓解定义为尿蛋白排泄<0.3 g/d。
  • CR36指第36周时达到CR,CR110指至第110周任意时间达到CR。

临床怎么用

  • IgA肾病患者治疗中应尽可能将蛋白尿降至<0.3 g/d以保护肾功能。
  • 达到完全蛋白尿缓解者eGFR下降更慢、肾衰竭事件更少。

局限性

  • 该分析为PROTECT试验的事后分析,非预设主要分析。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: This analysis explored the association between complete remission of proteinuria and kidney function decline during sparsentan or irbesartan treatment. Patients achieving complete remission of proteinuria experienced better eGFR preservation and fewer kidney failure events. These data support Kidney Disease Improving Global Outcomes guideline recommendations to maintain proteinuria levels in IgA nephropathy ideally below 0.3 g/d. BACKGROUND: In the phase 3, randomized, double-blind PROTECT ( NCT03762850 ) trial, sparsentan, a single-molecule dual endothelin angiotensin receptor antagonist, reduced proteinuria and preserved kidney function compared with maximum labeled dose irbesartan in adults with IgA nephropathy. In this post hoc analysis of PROTECT, we assessed the association between complete remission of proteinuria (CR) and preservation of kidney function. METHODS: This analysis compared kidney function in patients who achieved CR (urine protein excretion <0.3 g/d) by week 36 (CR36) or at any time up to week 110 (CR110) versus those who did not (non-CR), regardless of original treatment allocation. End points assessed by CR status were change in proteinuria, eGFR, and BP, rate of eGFR decline, a composite kidney end point, and safety. RESULTS: Of 404 patients who were randomized and received study drug, 43 (11%) achieved CR36 and 85 (21%) achieved CR110. CR patients demonstrated greater and more rapid reductions in proteinuria compared with non-CR patients. CR110 patients had a smaller absolute change in eGFR versus non-CR patients (-4.0 versus -8.6 ml/min per 1.73 m 2 ) and a slower rate of eGFR decline (day 1-week 110; -0.7 versus -4.2 ml/min per 1.73 m 2 per year). Fewer CR110 patients (1%) reached the composite kidney end point versus non-CR patients (14%). CR110 patients were more likely to experience treatment-emergent adverse events associated with hypotension (hypotension, orthostatic hypotension, or BP systolic decreased) and less likely to experience treatment-emergent adverse events of hypertension than non-CR patients. More non-CR patients versus CR110 patients discontinued treatment due to AEs (11% versus 4%, respectively) or patient decision (8% versus 2%, respectively). CONCLUSIONS: Participants in PROTECT who achieved CR36 or CR110 showed greater eGFR preservation, fewer kidney failure events, and similar safety profiles compared to non-CR participants. These data reinforce recommendations to maintain proteinuria levels ideally <0.3 g/d and underscore its relationship with kidney function preservation. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT03762850 .

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Rovin BH, Komers R, et al. Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy. Clin J Am Soc Nephrol. 2025. PMID: 41428405. doi:10.2215/CJN.0000000961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。